ReviewAmerican journal of cancer research2026
Prognostic value of absolute global longitudinal strain for chemotherapy-related cardiac dysfunction in breast cancer patients: a systematic review and meta-analysis.
Review in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the general predictive effect of absolute global longitudinal strain (GLS) in predicting chemotherapy-induced cardiotoxicity (CTRCD) for breast cancer patients.
methodsA systematic literature search was conducted on the PubMed, Embase, Cochrane Library, Web of Science, Scopus, China National Knowledge Infrastructure (CNKI), Wanfang and VIP databases to identify cohort studies published up to May 31, 2026, on the application of GLS for predicting CTRCD in breast cancer patients undergoing chemotherapy. Two researchers independently carried out the article filtering, data collection and quality assessment. RevMan 5.4 and Stata 18.0 software were used for meta-analysis; the size of the general effect was presented as an odds ratio (OR), and a hierarchical summary receiver operating characteristic (HSROC) curve was constructed to assess diagnostic accuracy. Subgroup analysis and meta-regression were used to identify the sources of heterogeneity; sensitivity analysis was conducted by a stepwise exclusion strategy; and a funnel plot was employed to examine publication bias.
result12 papers included data from 955 breast cancer patients. A meta-analysis indicated that the odds of being affected by CTRCD were significantly higher in the low-GLS group (absolute drop in GLS) compared with the high-GLS group (OR = 11.88, 95% CI: 7.88-17.92, P<0.00001), and there was low heterogeneity across trials (I
conclusionthe absolute GLS value can be used as a good prognostic index for chemotherapy-induced CTRCD in breast cancer patients, and a lower absolute GLS is associated with a significantly increased risk of CTRCD. An index has been developed to determine the risk of damage to the heart muscle after chemotherapy in breast cancer at a specific time, and scientific support will be provided for treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.